If biotech companies believed that sellers by now had wrung the sector dry, last week's roiled stock markets revealed that biotech equities could fall even more - and fall a lot.

The BioCentury 100 index plunged 12 percent, the largest weekly fall since the index began tracking the sector's price level in October 1992.